Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.59 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2776947 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2KDM4EGAAMEN1KMT2A | |
| SCHEMBL16563402 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2KDM4EGAAMEN1KMT2A | |
| SCHEMBL13268902 | 0.85 | SMN1; SMN2 (0.64) | SMN1; SMN2KDM4EGAAMEN1KMT2A | |
| SCHEMBL5918214 | 0.84 | SMN1; SMN2 (0.68) | SMN1; SMN2KDM4EALDH1A1NR1I2CES2 | |
| SCHEMBL8025191 | 0.84 | SMN1; SMN2 (0.68) | SMN1; SMN2KDM4EALDH1A1NR1I2CES2 | |
| SCHEMBL8968658 | 0.84 | SMN1; SMN2 (0.68) | SMN1; SMN2KDM4EALDH1A1NR1I2CES2 | |
| SCHEMBL23019763 | 0.84 | GAA (0.61) | SMN1; SMN2KDM4EGAAMEN1KMT2A | |
| SCHEMBL6069211 | 0.84 | GAA (0.61) | SMN1; SMN2KDM4EGAAMEN1KMT2A | |
| SCHEMBL28738527 | 0.82 | SMN1; SMN2 (0.66) | SMN1; SMN2KDM4EALDH1A1NR1I2CES2 | |
| SCHEMBL27838330 | 0.82 | SMN1; SMN2 (0.66) | SMN1; SMN2KDM4EMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113891882-A | Method for producing dihydroisoxazole | 组合化学工业株式会社 | 2022-01-04 | — | — | CN | disclosed |
| US-10017508-B2 | Nitrogenated heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-10 | — | — | US | disclosed |
| EP-2848618-B1 | NITROGENATED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-03-14 | — | — | EP | disclosed |
| US-20170129887-A1 | NITROGENATED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-05-11 | — | — | US | disclosed |
| US-9469637-B2 | Nitrogenated heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-18 | — | — | US | disclosed |
| US-20150105373-A1 | NITROGENATED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
| EP-2848618-A1 | NITROGENATED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-03-18 | — | — | EP | disclosed |
| US-8933240-B2 | Synthesis for thiazolidinedione compounds | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2015-01-13 | — | — | US | disclosed |
| EP-2227475-B1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | FIBROGEN INC (US) | 2014-02-19 | — | — | EP | disclosed |
| US-20130204008-A1 | NOVEL SYNTHESIS FOR THIAZOLIDINEDIONE COMPOUNDS | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2013-08-08 | — | — | US | disclosed |
| US-6844359-B2 | Substituted imides | CELGENE CORPORATION (US) | 2005-01-18 | — | — | US | disclosed |
| US-20020143027-A1 | Novel substituted imides | MULLER GEORGE W (US) | 2002-10-03 | — | — | US | disclosed |
| US-6429221-B1 | INHIBITORS OF TUMOR NECROSIS FACTOR; USED TO TREAT CACHEXIA, ENDOTOXIC SHOCK, AND RETROVIRUS REPLICATION | CELGENE CORPORATION | 2002-08-06 | — | — | US | disclosed |
| US-6235786-B1 | RHEUMATIC DISORDERS; BONE DISORDERS; ORAL DISEASES; ANTIULCER AGENTS; ANTITUMOR AGENTS | ABBOTT LABORATORIES | 2001-05-22 | — | — | US | disclosed |
| US-6225463-B1 | REACTING S-AMINE COMPOUND WITH AN ALDEHYDE; REACTING WITH ACYL CHLORIDE IN PRESENCE OF TRIETHYLAMINE TO FORM DIASTEREOISOMERIC BETA-LACTAMS; SEPARATION; TREATING WITH CERIUM AMMONIUM NITRATE AND ACETONITRILE AND WATER | PHARMACHEMIE B.V. (NL) | 2001-05-01 | — | — | US | disclosed |
| EP-0933360-A1 | Synthesis of new beta-lactams | PHARMACHEMIE B.V. (NL) | 1999-08-04 | — | — | EP | disclosed |
| EP-0800514-A1 | SUBSTITUTED IMIDES AS TNF INHIBITORS | CELGENE CORPORATION (US) | 1997-10-15 | — | — | EP | disclosed |
| WO-1996020926-A9 | SUBSTITUTED IMIDES AS TNF INHIBITORS | — | 1996-09-26 | — | — | WO | disclosed |
| WO-1996020926-A1 | SUBSTITUTED IMIDES AS TNF INHIBITORS | CELGENE CORPORATION (US) | 1996-07-11 | — | — | WO | disclosed |
| US-4032644-A | HYPOLIPIDEMIC AGENTS | SANDOZ, INC. (US) | 1977-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105373-A1 | NITROGENATED HETEROCYCLIC COMPOUND | PDE2A, PDE5A, PDE3A | SMN1; SMN2 534/4885KDM4E 1317/4885GAA 851/4885 |
| US-20020143027-A1 | Novel substituted imides | TNF, MIF, TNFRSF1A | SMN1; SMN2 312/4885KDM4E 276/4885GAA 1882/4885 |
| US-20170129887-A1 | NITROGENATED HETEROCYCLIC COMPOUND | PDE2A, PDE5A, PDE3A | SMN1; SMN2 534/4885KDM4E 1317/4885GAA 851/4885 |
| US-20130204008-A1 | NOVEL SYNTHESIS FOR THIAZOLIDINEDIONE COMPOUNDS | PPARG, PPARD, PPARA | SMN1; SMN2 4850/4885KDM4E 1814/4885GAA 3026/4885 |
| US-10017508-B2 | Nitrogenated heterocyclic compound | PDE2A, PDE5A, PDE3A | SMN1; SMN2 534/4885KDM4E 1317/4885GAA 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.